Glucagon-like peptide1 receptor agonists
In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
1. A compound of the formula:
wherein
R 1 is H or F;
R 2 is H; and
R 3 is CH 3 ;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 3 , which is the tert-butylamine salt of:
5. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 and at least one pharmaceutically acceptable carrier, diluent, or excipient.
6. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 3 and at least one pharmaceutically acceptable carrier, diluent, or excipient.
7. A method of treating type II diabetes mellitus in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
8. The method according to claim 7 , wherein the compound is administered orally.
9. A method of lowering blood glucose levels in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
10. The method according to claim 9 , wherein the compound is administered orally.
11. A method of treating hyperglycemia in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 , wherein the compound is administered orally.
13. A method of treating type II diabetes mellitus in a mammal comprising administering to the mammal an effective amount of a compound according to claim 3 , or a pharmaceutically acceptable salt thereof.
14. The method according to claim 13 , wherein the compound is administered orally.
15. A method of lowering blood glucose levels in a mammal comprising administering to the mammal an effective amount of a compound according to claim 3 , or a pharmaceutically acceptable salt thereof.
16. The method according to claim 15 , wherein the compound is administered orally.
17. A method of treating hyperglycemia in a mammal comprising administering to the mammal an effective amount of a compound according to claim 3 , or a pharmaceutically acceptable salt thereof.
18. The method according to claim 17 , wherein the compound is administered orally.